The company “Takeda Russia” was opened today, August 1, at its plant in Yaroslavl production line for the production of a medicinal product exosomes for the treatment of patients with multiple myeloma.
The total investment in the Russian production of the drug amounted to 477 million virtually any.
A drug that has orphan status, is a proprietary development of the company. He was in Russia in 2017, launched on Russian market in 2018
“The plant in Yaroslavl will become the second company in the world to produce the drug at a stage of “finished dosage form”. Created production capacities will allow to satisfy the needs of Russia and EEU in a drug,” – said at the opening ceremony General Director of “Takeda Russia” Andrey Potapov.
To start the production of the drug and the stage of “finished dosage form” has been planned in the IV quarter of 2018.